Related references
Note: Only part of the references are listed.Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis
Sarah C. MacDonald et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2019)
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Ai-Lan Nguyen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review
Patricia K. Coyle et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks
Emilio Portaccio et al.
NEUROLOGY (2018)
Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era
Raed Alroughani et al.
NEUROLOGY (2018)
Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS
Maria K. Houtchens et al.
NEUROLOGY (2018)
Treatment of multiple sclerosis during pregnancy - safety considerations
Jan Thoene et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Evolving concepts in the treatment of relapsing multiple sclerosis
Giancarlo Comi et al.
LANCET (2017)
Glatiramer acetate during early pregnancy: A prospective cohort study
Sandra Herbstritt et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Interferon-beta exposure during first trimester is safe in women with multiple sclerosisA prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry
Sandra Thiel et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Glatiramer acetate during early pregnancy: A prospective cohort study
Sandra Herbstritt et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Interferon-beta exposure during first trimester is safe in women with multiple sclerosisA prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry
Sandra Thiel et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study
Neda Ebrahimi et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs
E. Lu et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Disease-modifying drugs for multiple sclerosis in pregnancy A systematic review
Ellen Lu et al.
NEUROLOGY (2012)
Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study
C. Weber-Schoendorfer et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy:: a descriptive study in the Spanish population
V. De las Heras et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
The reproductive effects of beta interferon therapy in pregnancy - A longitudinal cohort
R Boskovic et al.
NEUROLOGY (2005)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)